Lepu Biopharma Co., Ltd. (02157.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

168.2x

Market Cap

HKD 7.63B

MomentumView details →

1D Return

+0.69%

YTD Return

−12.47%

RSI (14)

51.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

168.2x

Market Cap

HKD 7.63B

RSI (14)

51.5

MomentumView details →

1D Return

+0.69%

YTD Return

−12.47%

ProfitabilityView details →

Gross Margin

82.98%

Net Margin

3.92%

EBITDA Margin

2.45%

ROE (TTM)

4.65%

ROA (TTM)

2.08%

Asset Turnover

0.54x

GrowthView details →

Revenue YoY

+348.34%

EPS YoY

+107.94%

FCF YoY

+88.74%

Revenue CAGR 3Y

+288.16%

EPS CAGR 3Y

+158.33%

EBITDA YoY

+105.68%

EarningsView details →

EPS (Actual)

HKD 0.02

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.84x

Current Ratio

1.14x

Quick Ratio

1.07x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

1.68B

Net Income (TTM)

65.77M

Op. CF (TTM)

—

Next earningsMar 31, 2027 →

Latest newsMore news →

Lepu Biopharma announced its interim results for the six months ended June 2026, with revenue of RMB 522 million, up 12.1% year-on-year, and net profit of RMB 27.39 million, down 34.4% year-on-year.16d ago

Similar companies

苑东生物688513.SH Alkermes plcALKS CARsgen Therapeutics Holdings Limited02171.HK Belite Bio, IncBLTE Spyre Therapeutics, Inc.SYRE Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H02335.HK Find similar companies →

Latest newsMore news →

Lepu Biopharma announced its interim results for the six months ended June 2026, with revenue of RMB 522 million, up 12.1% year-on-year, and net profit of RMB 27.39 million, down 34.4% year-on-year.16d ago